Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 14, 2022
Discovery & Translation
Codiak’s pan beta-coronavirus vaccine; plus CNS-penetrating AAV9 variants and more
BioCentury’s roundup of translational news
BioCentury | Apr 27, 2022
Data Byte
Europe’s biggest biotech venture rounds so far this year
Eight European therapeutics developers have raised venture rounds of at least $50M year-to-date
BioCentury | Mar 29, 2022
Data Byte
Three radiotherapy companies have raised over $200M in 1Q22
March fund-raisings equate to over 80% of 2021’s total venture capital raised and almost two-thirds of 2020’s total
BioCentury | Mar 18, 2022
Finance
Precirix building out radiotherapy platform with €80M series B
The Belgian company is branching out into alpha emitters and growing its geographical footprint
BioCentury | Sep 25, 2021
Translation in Brief
Verve’s durable PCSK9 base editor; plus Novartis, PureTech and more
BioCentury’s roundup of translational news
BioCentury | Nov 7, 2020
Product Development
Amgen’s adaptive solution to lupus
Amgen tackles clinical development challenges in lupus with an adaptive trial design
BioCentury | Oct 16, 2020
Product Development
Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to
Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year
BioCentury | Oct 15, 2020
Emerging Company Profile
RayzeBio pulling together radiotherapy platform with $45 million
RayzeBio combines the tumor-killing of actinium 225 with the target affinity and PK of macrocycles
BioCentury | Oct 9, 2020
Translation in Brief
Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine
BioCentury’s roundup of translational news
BioCentury | Jun 19, 2020
Deals
In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program
Items per page:
1 - 10 of 192